GlassScriptPhysician profile
James True Martin
NPI 1982671053
$11,681.07
in general payments reported to CMS, 2019-2025
67 companies · $2,239 in 2025
The $2,239 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,037 · 2020: $846 · 2021: $808 · 2022: $1,516 · 2023: $1,731 · 2024: $2,504 · 2025: $2,239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,473.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $971.58 | 2019-2025 | |
| Abbvie INC. | $735.89 | 2019-2025 | |
| Ucb, INC. | $708.35 | 2020-2025 | Nayzilam, Zilbrysq, Fintepla |
| Lilly USA, LLC | $670.02 | 2022-2025 | Emgality, Kisunla, Amyvid |
| Lundbeck LLC | $612.06 | 2020-2025 | Vyepti, Rexulti |
| Sk Life Science, INC. | $595.92 | 2020-2025 | |
| Amgen INC. | $485.53 | 2019-2025 | Uplizna |
| Greenwich Biosciences, INC. | $481.47 | 2019-2021 | |
| Jazz Pharmaceuticals INC. | $466.95 | 2019-2025 | Epidiolex |
| Alexion Pharmaceuticals, INC. | $452.09 | 2019-2025 | Ultomiris, Soliris |
| Eisai INC. | $449.06 | 2019-2025 | |
| Supernus Pharmaceuticals, INC. | $377.90 | 2019-2022 | |
| Neurelis, INC. | $376.28 | 2020-2025 | Valtoco |
| Teva Pharmaceuticals USA, INC. | $363.87 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Catalyst Pharmaceuticals, INC. | $292.62 | 2019-2025 | Fycompa, Firdapse |
Show all 66 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,633,200.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.